Biologically active dietary supplement for correction of exchange disorders in nervous system diseases

The prescription composition of the biologically active dietary supplement (BADS) Oleopren Neuro has been scientifically substantiated through the pharmacological evaluation of the effective agents, polyprenols being the main of them. The technology of an innovative product has been developed, with the establishment of adjustable production parameters securing high organoleptic advantages and stability of the BADS. Regulated indicators of quality and nutritional value have been determined. Sanitary toxicological and hygienic safety indicators of the product under development had been studied, which allowed to establish a shelf life of two years taking the safety margin of three months into account. The possible mechanisms of the dolichols effect on the metabolic status of the organism were considered. Clinical trials of the efficiency and functional focus of a specialized product on a representative group of patients with the dyscirculatory encephalopathy (DE) of vascular genesis stages I ­ II were conducted. The BADS were included in the diet of patients, along with the basic therapy, one capsule twice a day for 10 days. The materials obtained in this article allow to recommend the developed product as an efficient means of increasing the body's resistance to adverse effects of the environment, stressful situations, as well as psychoemotional and physical stress.

[Effectiveness of the new plant hepatoprotector--Ropren in patients with non-alcoholic steatohepatitis].

Liver damage causes serious metabolic disorders, immune response, detoxification functions and antimicrobial protection. Therefore, the problem of finding new high effective drugs for the restoration and normalization of liver function is extremely urgent. This article presents a new domestic plant hepatoprotector Ropren, which is a biopolymer polyprenols isolated from the green of pine and spruce, and an analog of the endogenous lipid--dolichol. Presented the Ropren efficiency in patients with nonalcoholic steatohepatitis. The drug reduces the clinical and biochemical disease activity, contributes to the normalization of lipid profile. The resulting decrease in the index treatment of fibrosis, determined by indirect transient elastometry, indicates an increase in the elasticity of the liver and reducing the risk of developing cirrhosis.